Naoto Kamiya1, Hiroyoshi Suzuki2, Takahito Suyama3, Masayuki Kobayashi4, Satoshi Fukasawa4, Nobuyuki Sekita5, Kazuo Mikami5, Naoki Nihei6, Yukio Naya3, Tomohiko Ichikawa6. 1. Department of Urology, Toho University Sakura Medical Center, 564-1 Shimoshizu, Sakura, Chiba, 285-8741, Japan. naoto.kamiya@med.toho-u.ac.jp. 2. Department of Urology, Toho University Sakura Medical Center, 564-1 Shimoshizu, Sakura, Chiba, 285-8741, Japan. 3. Department of Urology, Teikyo University Chiba Medical Center, 3426-3 Anesaki, Ichihara, Chiba, 299-0111, Japan. 4. Department of Urology, Chiba Cancer Center, 662-2 Nitona-cho, Chuou-ku, Chiba, 260-8717, Japan. 5. Department of Urology, Chibaken Saiseikai Narashino Hospital, 1-1-1 Izumi-cho, Narashino, Chiba, 275-8580, Japan. 6. Department of Urology, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba, 260-8670, Japan.
Abstract
BACKGROUND: A retrospective, multi-institutional collaborative study was conducted to evaluate the impact of second transurethral resection (TUR) on the clinical outcome of non-muscle invasive high-grade bladder cancer and to identify predictors of invasion to the lamina propria (pT1) or deeper and residual tumor at the second TUR. METHODS: The clinical and pathological features of 198 patients with non-muscle invasive high-grade bladder cancer treated in five medical institutions from April 1990 to March 2013 were reviewed retrospectively. All patients underwent a second TUR within a mean of 1.5 months after the first resection. Clinicopathological findings of the first and second TURs were compared. Cancer-specific survival and recurrence-free survival were evaluated. Univariate and multivariate analyses for predictors of residual cancer at the second TUR were performed using a logistic regression model. RESULTS: At the second TUR, no tumor was found in 111 (56 %) patients, and 87 (44 %) had residual cancer. At the first TUR, five pT1 patients (3 %) were upstaged to pT2, one pTa patient (1 %) was upstaged to pT1, and 12 G2 patients (6 %) had their tumor upgraded to G3. Patients the group with less than stage pT1 cancer at the second TUR had significantly better survival than those in the group with stage pT1 or deeper cancer. Tumor multiplicity at the first resection was an independent risk factor for pT1 or deeper tumor at the second TUR. CONCLUSION: A second TUR is a valuable diagnostic procedure for accurate staging of non-muscle invasive high-grade bladder cancer. Tumor multiplicity at the first TUR was a significant independent predictor of pT1 or deeper tumor at the second TUR.
BACKGROUND: A retrospective, multi-institutional collaborative study was conducted to evaluate the impact of second transurethral resection (TUR) on the clinical outcome of non-muscle invasive high-grade bladder cancer and to identify predictors of invasion to the lamina propria (pT1) or deeper and residual tumor at the second TUR. METHODS: The clinical and pathological features of 198 patients with non-muscle invasive high-grade bladder cancer treated in five medical institutions from April 1990 to March 2013 were reviewed retrospectively. All patients underwent a second TUR within a mean of 1.5 months after the first resection. Clinicopathological findings of the first and second TURs were compared. Cancer-specific survival and recurrence-free survival were evaluated. Univariate and multivariate analyses for predictors of residual cancer at the second TUR were performed using a logistic regression model. RESULTS: At the second TUR, no tumor was found in 111 (56 %) patients, and 87 (44 %) had residual cancer. At the first TUR, five pT1patients (3 %) were upstaged to pT2, one pTa patient (1 %) was upstaged to pT1, and 12 G2 patients (6 %) had their tumor upgraded to G3. Patients the group with less than stage pT1cancer at the second TUR had significantly better survival than those in the group with stage pT1 or deeper cancer. Tumor multiplicity at the first resection was an independent risk factor for pT1 or deeper tumor at the second TUR. CONCLUSION: A second TUR is a valuable diagnostic procedure for accurate staging of non-muscle invasive high-grade bladder cancer. Tumor multiplicity at the first TUR was a significant independent predictor of pT1 or deeper tumor at the second TUR.
Entities:
Keywords:
Bladder cancer; Non-muscle invasive high-grade; Second transurethral resection
Authors: Simone Bertz; Stefan Denzinger; Wolfgang Otto; Wolf F Wieland; Robert Stoehr; Ferdinand Hofstaedter; Arndt Hartmann Journal: Histopathology Date: 2011-10 Impact factor: 5.087
Authors: Maximilian Burger; James W F Catto; Guido Dalbagni; H Barton Grossman; Harry Herr; Pierre Karakiewicz; Wassim Kassouf; Lambertus A Kiemeney; Carlo La Vecchia; Shahrokh Shariat; Yair Lotan Journal: Eur Urol Date: 2012-07-25 Impact factor: 20.096
Authors: Marko Babjuk; Maximilian Burger; Richard Zigeuner; Shahrokh F Shariat; Bas W G van Rhijn; Eva Compérat; Richard J Sylvester; Eero Kaasinen; Andreas Böhle; Joan Palou Redorta; Morgan Rouprêt Journal: Eur Urol Date: 2013-06-12 Impact factor: 20.096
Authors: Morgan Rouprêt; Thomas Seisen; Eva Compérat; Stéphane Larré; Catherine Mazerolles; Françoise Gobet; Franck Fetissof; Gaelle Fromont; Athmane Safsaf; Benjamin Faivre d'Arcier; Olivier Celhay; Pierre Validire; François Rozet; Jacques Irani; Michel Soulié; Christian Pfister Journal: J Urol Date: 2012-11-28 Impact factor: 7.450
Authors: Matteo Ferro; Giuseppe Di Lorenzo; Carlo Buonerba; Giuseppe Lucarelli; Giorgio Ivan Russo; Francesco Cantiello; Abdal Rahman Abu Farhan; Savino Di Stasi; Gennaro Musi; Rodolfo Hurle; Serretta Vincenzo; Gian Maria Busetto; Ettore De Berardinis; Sisto Perdonà; Marco Borghesi; Riccardo Schiavina; Gilberto L Almeida; Pierluigi Bove; Estevao Lima; Giovanni Grimaldi; Deliu Victor Matei; Francesco Alessandro Mistretta; Nicolae Crisan; Daniela Terracciano; Verze Paolo; Michele Battaglia; Giorgio Guazzoni; Riccardo Autorino; Giuseppe Morgia; Rocco Damiano; Matteo Muto; Roberto La Rocca; Vincenzo Mirone; Ottavio de Cobelli; Mihai Dorin Vartolomei Journal: J Cancer Date: 2018-10-20 Impact factor: 4.207
Authors: Anna Katarzyna Czech; Katarzyna Gronostaj; Jakub Frydrych; Jakub Fronczek; Mikołaj Przydacz; Tomasz Wiatr; Łukasz Curyło; Przemysław Dudek; Jerzy Gąsowski; Piotr L Chłosta Journal: Cent European J Urol Date: 2019-09-16